X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sinopharm's mRNA-based COVID-19 vaccine was developed using the traditional method, by means of an inactivated virus, in this case the coronavirus, which causes COVID-19 - is killed or modified in such a way that it is unable to replicate.
Lead Product(s): mRNA-based COVID-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ChromaDex, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 10, 2022
Details:
The partnership will accelerate stockpiling, channel distribution and regional access of the amubarvimab/romlusevimab combination. Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID-19.
Lead Product(s): Amubarvimab,Romlusevimab
Therapeutic Area: Infections and Infectious Diseases Product Name: BRII-196
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Brii Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 30, 2022
Details:
BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell), indicated the potential of BBIBP-CorV to provide cross-protection against other SARS-CoV-2 strains.
Lead Product(s): Inactivated SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: BBIBP-CorV
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA.
Lead Product(s): Inactivated Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2021
Details:
MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against COVID-19 infection.
Lead Product(s): Inactivated Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Beijing Institute of Biological Product
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Sinopharm's Vero cell is under Phase III randomized, double blind trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 Vaccines in healthy population aged 18 years old and above.
Lead Product(s): Inactivated SARS-CoV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Vero cell
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Shanghai Fosun Pharmaceutical has signed a strategic cooperation agreement with Sinopharm Group to supply a coronavirus vaccine candidate developed by German firm BioNTech.
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 07, 2020
Details:
Sinopharm's inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.
Lead Product(s): Inactivated Covid-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2020
Details:
Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
